Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.

A study that assessed the risk of diabetic ketoacidosis after the initiation of SGLT2 inhibitor therapy showed nearly twice the risk as with a DPP4 inhibitor.

[1]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[2]  JA Rassen,et al.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. , 2016, Clinical pharmacology and therapeutics.

[3]  W. Ogawa,et al.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors , 2015, Journal of diabetes investigation.

[4]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[5]  A. Tahrani,et al.  SGLT inhibitors in management of diabetes. , 2013, The lancet. Diabetes & endocrinology.